anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron hydrochloride tablets. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization, and rarely, blood transfusion, surgery, and death.

  * Alosetron hydrochloride tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy [see Indications and Usage (1)] .
  * Alosetron hydrochloride tablets should be discontinued immediately in patients who develop constipation or symptoms of ischemic colitis. Patients should immediately report constipation or symptoms of ischemic colitis to their prescriber. Alosetron hydrochloride tablets should not be resumed in patients who develop ischemic colitis. Patients who have constipation should immediately contact their prescriber if the constipation does not resolve after alosetron hydrochloride tablets are discontinued. Patients with resolved constipation should resume alosetron hydrochloride tablets only on the advice of their treating prescriber [see Dosage and Administration (2.1), Warnings and Precautions (5.1), (5.2)].
Participants in this group engage in the traditional core course, followed by a 20-minute practical session where they pair up for mutual hands-on practice. The assessment of upper limb soft tissue operations takes approximately 4 minutes per session, allowing for approximately 5 practice sessions.
Our case-control study will enroll subjects with a spontaneous ICH in the Greater Cincinnati region. For each subject enrolled we will also enroll a healthy control subject(matched by age , race and gender). Both the cases and control will undergo the same interview and have blood drawn for genetic analysis. The cases will have a chart abstraction done on their event medical record and be contacted for 3 and 6 month follow up(short interview). The genetic sample will be genotyped using the Affymetrix 6.0 gene chip looking for SNPs of interest and to identify genetic variants associated with ICH. The most promising SNPs identified through this process will be replicated in the external cohort from Massachusetts General Hospital.
Albumin infusions improve circulatory and renal function in patients with decompensated cirrhosis. However, there is no convincing evidence that hypoalbuminemia contributes to ascites formation in liver cirrhosis. The aim of our study is to determine the exact role of hypoalbuminemia in the formation of ascites caused by liver cirrhosis and its underlying mechanism. Clinical profiles of patients with liver cirrhosis retrospectively analyzed. The details of albumin involved in ascites formation were investigated in rat model and murine model. Statistical analysis demonstrated hypoalbuminemia was an independent risk factor for ascites formation in patients with liver cirrhosis (OR = 0.722, P < 0.001). In carbon tetrachloride (CCl4)-induced rat model of liver cirrhosis, a significant reduction in serum albumin was observed in rats with ascites (13.37 g/L) compared with rats without ascites (21.43 g/L, P < 0.001). In thioacetamide (TAA)-treated mice, ascites amount of heterozygous albumin (Alb+/-) mice (112.0 mg) was larger than that of wild-type (Alb+/+) mice (58.46 mg, P < 0.001). In CCl4-induced chronic liver injury, ascites amounts of Alb+/- or Alb+/+ mice were 80.00 mg or 48.46 mg (P = 0.001). Further study demonstrated 24-h urinary sodium excretion in Alb+/- mice was lower than that of Alb+/+ mice in TAA/CCl4-induce murine models of liver cirrhosis. Additionally, serum sodium concentration of Alb+/- mice was lower than that of Alb+/+ mice. In cirrhotic mice, higher level of antidiuretic hormone was observed in Alb+/- mice compared with the control; and renal aquaporin (AQP2) expression in Alb+/- mice was significantly higher than that of WT mice. These revealed hypoalbuminemia contributed to the occurrence of ascites in liver cirrhosis through sodium and water retention.
The invention provides a xylo-oligosaccharide composition with a lipase activity inhibition effect. The xylo-oligosaccharide composition comprises xylo-oligosaccharide and L-arabinose. The composition has greater lipase activity inhibition effect than the single xylo-oligosaccharide or L-arabinose. The cooperative effect can be realized when the proportion of the xylo-oligosaccharide to the L-arabinose is 1:99 to 99:1 in the composition, the inhibition rate is greater than the maximum inhibition rate of the single ingredients when the proportion of the xylo-oligosaccharide to the L-arabinose in the composition is 1:99 to 45:55, and in addition, the optimized proportion is 40:60. The invention also provides hypolipidemic medicine, food, pet food and health care products. The medicine, the food, the pet food and the health care products comprise the composition disclosed by the invention. The composition provided by the invention has the advantages that the resources of raw materials are wide, the raw materials are easy to obtain, the cost is low, the functions are various, and the targeting is specific when the composition is applied to hypolipidemic products.
<P>PROBLEM TO BE SOLVED: To provide a medical implant that delivers a therapeutic agent via microtubes and a manufacturing method thereof.  <P>SOLUTION: In one embodiment, a biologically implantable structure adapted to fit within the body of a patient is provided. This structure may have a plurality of individual microtubes in physical communication with its outer surface, the microtubes containing or carrying a therapeutic agent. In an alternative embodiment, a method of manufacturing an implantable medical appliance is provided. This method includes placing a pliant stratum of microtubes onto a biologically implantable medical structure and then applying a therapeutic agent to the pliant stratum to cover or fill the microtubes.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The disclosure provides compositions and methods for suppressing Hepatitis B virus (HBV) in an infected cell. Exemplary methods comprise contacting the infected cell with one or more agents that induce interferon regulatory factor 3 (IRF3) activation in the infected cell. In some embodiments, the one or more agents comprises pathogen‑associated molecular pattern (PAMP)‑containing nucleic acid molecule, a small molecule agent (e.g., a benzothiazol-derivative molecule), or a combination thereof. In some embodiments, the method further comprises contacting the infected cell with a NRTI. The method can be an in vivo method of treating a subject with HBV infection, comprising administering therapeutically relevant amounts of one or more agents formulated in one or more therapeutically effect compositions. Exemplary compositions are formulated to treat a hepatitis B virus (HBV) infection in a subject, comprising: a RIG‑I agonist, a vehicle for intracellular delivery, and a pharmaceutically acceptable carrier.
For each cohort in Part A (SAD), 8 participants will be randomized in a 3:1 ratio; 6 participants to active (ADX-324): 2 participants to control (matched placebo). Randomization will be on Day 1. Initially, 2 sentinel participants (1 active and 1 placebo) will be randomized and dosed. The sentinel participants will be evaluated for safety. The investigator's assessment and the independent medical monitor will decide upon the randomization and dosing of the 6 remaining participants (5 active and 1 placebo) according to the randomization schedule.
Liver fibrosis is a terminal manifestation of various chronic liver diseases. There are no drugs that can reverse the condition. Recently, the importance of interleukin-17 (IL17) in the pathophysiology has been revealed and has attracted attention as a therapeutic target. We aimed to reveal the roles of IL17A and IL17F in liver fibrosis, and to validate the potential of their dual blockade as therapeutic strategy. First, we retrospectively reviewed the longitudinal change of FIB-4 index, a clinical indicator of liver fibrosis, among psoriasis patients treated by brodalumab, which blocks IL17 receptor A (IL17RA). Next, we examined anti-fibrotic efficacy of anti-IL17RA antibody (Ab) in two murine liver fibrosis models by histopathological investigation and real-time reverse transcription polymerase chain reaction (RT-PCR). Finally, we analyzed the effect of IL17A and IL17F upon human hepatic stellate cells with RNA sequencing, real-time RT-PCR, western blotting, chromatin immunoprecipitation, and flow cytometry. Clinical data showed that FIB-4 index significantly decreased among psoriasis patients treated by brodalumab. In vivo studies additionally demonstrated that anti-IL17RA Ab ameliorates liver fibrosis induced by tetrachloride and methionine-choline deficient diet. Furthermore, in vitro experiments revealed that both IL17A and IL17F enhance cell-surface expression of transforming growth factor-β receptor II and promote pro-fibrotic gene expression via the JUN pathway in human hepatic stellate cells. Our insights suggest that IL17A and IL17F share their pro-fibrotic function in the context of liver fibrosis, and moreover, dual blockade of IL17A and IL17F by anti-IL17RA Ab would be a promising strategy for the management of liver fibrosis.
The invention relates to a multiphase pharmaceutical product for oral hormonal contraception. The low-dose sequential or combination or phasic products are being increasingly used. All low-dose phasic products reliably inhibit the preovulatory LH peak. By contrast, follicle ripening is not completely blocked in every case. The object of the present invention is to administer hormones in analogy to the woman's normal physiological cycle throughout the cycle by creating an at least 4-phase combination product. The at least 4-phase pharmaceutical product for contraception consists according to the invention of a fixed or sequential at least 3-phase combination of ethinyloestradiol or mestranol or another synthetic oestrogen plus a progestogen and an oestrogen product which is to be administered at least in the 4th phase of the cycle and contains ethinyloestradiol or mestranol and/or another synthetic and/or endogenous oestrogen.
The invention provides an adriamycin bonding medicine which has a structure shown as a formula I or a formula II. The method for preparing the adriamycin bonding medicine provided by the invention comprises the following steps: enabling an adriamycin derivative with a structure shown as a formula III or a formula V to react with a compound with a structure shown as a formula IV, thereby obtaining the adriamycin bonding medicine. The invention further provides a physical gel comprising the adriamycin bonding medicine and an inorganic solvent according to a mass ratio of (10-30): (90-70). The physical gel provided by the invention is in a solution state at the temperature of 25 DEG C or below, and along with the temperature rise, the physical gel is in a gelling state. Therefore, the physical gel provided by the invention is in a gelling state in vivo, the action time of the adriamycin at a tumor part can be prolonged, and the long-acting treatment effect of the adriamycin is enhanced. Moreover, the physical gel provided by the invention can be used for loading other antitumor medicines with the same action mechanism or different action mechanisms, and the antitumor synergistic effect is enhanced.
OBJECTIVES: Stiripentol, fenfluramine, and cannabidiol are licensed add-on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first-line add-on therapies in DS.
METHODS: We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trial (RCT) data for licensed add-on DS therapies. We compared the proportions of patients experiencing: reductions from baseline in monthly convulsive seizure frequency (MCSF) of ≥50% (clinically meaningful), ≥75% (profound), and 100% (seizure-free); serious adverse events (SAEs); discontinuations due to AEs.
RESULTS: We identified relevant data from two placebo-controlled RCTs for each drug. Stiripentol 50 mg/kg/day and fenfluramine 0.7 mg/kg/day had similar efficacy in achieving ≥50% (clinically meaningful) and ≥75% (profound) reductions from baseline in MCSF (absolute risk difference [RD] for stiripentol versus fenfluramine 1% [95% confidence interval: -20% to 22%; p = 0.93] and 6% [-15% to 27%; p = 0.59], respectively), and both were statistically superior (p < 0.05) to licensed dose regimens of cannabidiol (10 or 20 mg/kg/day, with/irrespective of clobazam) for these outcomes. Stiripentol was statistically superior in achieving seizure-free intervals compared to fenfluramine (RD = 26% [CI: 8% to 44%; p < 0.01]) and licensed dose regimens of cannabidiol. There were no significant differences in the proportions of patients experiencing SAEs. The risk of discontinuations due to AEs was lower for stiripentol, although the stiripentol trials were shorter.
SIGNIFICANCE: This NMA of RCT data indicates stiripentol, as a first-line add-on therapy in DS, is at least as effective as fenfluramine and both are more effective than cannabidiol in reducing convulsive seizures. No significant difference in the incidence of SAEs between the three add-on agents was observed, but stiripentol may have a lower risk of discontinuations due to AEs. These results may inform clinical decision-making and the continued development of guidelines for the treatment of people with DS.
PLAIN LANGUAGE SUMMARY: This study compared three drugs (stiripentol, fenfluramine, and cannabidiol) used alongside other medications for managing seizures in a severe type of epilepsy called DS. The study found that stiripentol and fenfluramine were similarly effective in reducing seizures and both were more effective than cannabidiol. Stiripentol was the best drug for stopping seizures completely based on the available clinical trial data. All three drugs had similar rates of serious side effects, but stiripentol had a lower chance of being stopped due to side effects. This information can help guide treatment choices for people with DS.
NEW MATERIAL:An activation factor for fibrinolysin originating from organs and showing following properties: mol.wt., about 13,000 measured by SDS- polyacrylamide gel; spectrophotometric analyses reveal that maximum absorption peak near 408nm in the oxidized form and near 420nm in the form reduced with dithionite, and the pyridine-hemochromogen analyses show the maximum absorption near 420nm and a small absorptions near 525 and 557nm. USE:Prophylactic and remedy for liver cirrhosis. PREPARATION:For example, rat's fibrillated liver is homogenized to remove binding tissues or the like. Then, the residue is centrifuged to collect the cytoplasm fraction. 60% saturated ammonium sulfate is added to form precipitate, which is separated, dissolved in a buffer, then the solution is subjected to gel filtration. The eluted fraction is adsorbed on a carboxymethylagarose column, and eluted, further subjected to gel filtration to give the activation factor of fibrinolysin.
The participant will receive a session of myofunctional therapy every month, for 9 months. In this group, a series of procedures and techniques are carried out to create and mechanize muscular and orofacial patterns at rest and in function, eliminate habits, correct muscular imbalance, improve the aesthetics of the patient and normalize the functions of the stomatognathic system.
The WHO Standardized Acupuncture Points Location \[2\] will be used to identify the location of these acupoints, Tianshu(ST-25), Daheng(SP-15), Daimai(GB-24), Qihai(CV-6), Zhongwan(CV-12), Zusanli (ST-36), Fenlong(ST-40), and Sanyinjiao(SP-6). After sterilizing the skin, sterile adhesive pads will be pasted on acupoints first, and then needles of size 0.30\*75 mm will be inserted into the acupoints to a depth of 50 mm outward and upward slightly. Needles will be lifted, thrust, and twirled evenly 3 times to achieve "de-qi". Paired electrodes of the EA apparatus will be attached transversely to the acupoint respectively with a continuous wave of 50 Hz and a current intensity of 1-5 mA (preferably with the skin around the acupoints shivering mildly without pain) for 30 min. Patients will be treated with electroacupuncture 2 sessions per week over 8 consecutive weeks, 16 sessions for each patient.
PROBLEM TO BE SOLVED: To obtain flaky particles coated with titanium oxide on their surfaces which can impart a cosmetic with ultraviolet-screening effect, good spreadability, good feeling and good make-up finishing by formulating them to a cosmetic. SOLUTION: The surfaces of flaky particles, for example, of a smectite- layered clay mineral, as a kind of laminar clay mineral having three layers are coated with titanium oxide to prepare flaky coated particles of 0.001-0.2μm thickness. In the coating procedure, sol and/or gel of titanium oxide hydrate is combined with hydrogen peroxide to dissolve the titanium oxide hydrate, then the smectite clay mineral is added to the solution and heated. The amount of titanium oxide to be coated is >=4 pts.wt. calculated as TiO2 per 1 pt.wt. of the clay mineral. The flaky coated particles in an amount of 1-80wt.% are formulated to a cosmetic to give the objective cosmetic.
A method of maintaining personal viewing preferences when viewing medical imaging data is described, wherein the imaging data represents a plurality of anatomical regions acquired using a plurality of imaging modalities (e.g. PET,CT etc). The method comprises a set-up step 110 in which visualisation/viewing parameters/settings are stored 140 according to a users preference. The stored parameters 300 relate to viewing imaging data of a particular anatomical region which has been acquired using a given imaging modality. The stored parameters are made available for future use such that, when a user subsequently views similar/corresponding imaging data, the parameters are retrieved (180, figure 4) and used to configure the display of the imaging data in accordance with their personalised preferences. The method may also use segmentation techniques to automatically identify body regions. The method enables efficient configuration of display settings, thereby avoiding the need for a clinician to repetitively set viewing preferences upon each use of the system.
The invention provides an antibody against CD3 and a preparation method and application thereof. Specifically speaking, the invention discloses the antibody against CD3. The antibody has a heavy-chain variable region of a complementary determining region selected from the group consisting of a CDR 1 as shown in SEQ ID No. 11, a CDR 2 as shown in SEQ ID No. 12 and a CDR 3 as shown in SEQ ID No. 13. The antibody has the characteristic of specific binding with CD3 positive cells and can be used for separation of human CD3 positive cells and for preparation of a product used for separation of human CD3 positive cells; and separated cells can be used in clinical practice.
Oral lichen planus (OLP) is a chronic inflammatory oral condition previously known to have a rate of malignant transformation of around 1%. Additionally, erosive lichen planus, a subtype of lichen planus, which is a known risk factor for malignant transformation, has previously been unquantified in a large cohort of patients. In a single unit observation between 2005 and 2021 we retrospectively assessed 1,920 patients who underwent histological analysis for suspected oral lichen planus, and followed the progression of their disease to assess the rate of malignant transformation. In total, 1.39% of OLP transformed to oral squamous cell carcinoma over an average of 5.8 years. However, we found that the transformation rate of erosive OLP into malignancy was 5.98% with an aggressive clinical pathway. To our knowledge the incidence of erosive OLP has not previously been quantified in a large cohort of patients. This retrospective study sheds light on, and raises warning signs about, the seriousness of this condition.
FIELD: medicine, immunology. SUBSTANCE: extraction of an alcoholic precipitate B (Cohn's fraction III) is carried out in 10-fold volume of distilled water and sodium chloride (final concentration is 0.9%, by volume) is used for lipoprotein fraction removing. Immunoglobulin fraction is precipitated from extract in the presence of 12% polyethylene glycol. Content of inert impurities in preparation is 0-1% of total protein as compared with that 3-5% in prototype. Specific activity is increased by 2-3 times and the yield of preparation - by 1.5-fold. Net cost of the end product is decreased by 25% as compared with that in prototype. EFFECT: enhanced purity, increased specific activity and yield of preparation.
PROBLEM TO BE SOLVED: To provide a method for producing a low-molecular weight chitosan by which the low-molecular weight chitosan can inexpensively and stably be produced in large amounts and utilized for various fields and to provide a high-purity low-molecular weight chitosan suitable for utilization in the cutting-edge realm such as pharmaceuticals. SOLUTION: This method for producing the low-molecular weight chitosan comprises carrying out acid hydrolysis reaction of chitosan by using hydrochloric acid as a catalyst. The low-molecular weight chitosan having 10,000 to 20,000 weight-average molecular weight is preferably produced by the method. In the production method, acid hydrolysis reaction is carried out, preferably in >=3% hydrochloric acid concentration and a weight of >=5 times based on chitosan at >=40 deg.C decomposition temperature of chitosan, more preferably in 5-8% hydrochloric acid concentration and a weight of 8-16 times based on chitosan at 70-90 deg.C decomposition temperature. In the production method, membrane-separation is carried out after acid hydrolysis reaction.  The low-molecular weight chitosan is preferably composed of the low-molecular weight chitosan having 10,000 to 20,000 weight-average molecular weight and a high-purity low-molecular weight chitosan having nearly 10,000 weight average molecular weight. A composition comprising the low molecular weight chitosan, preferably food, cosmetic or medicine is also provided.
The Full Analysis Set (FAS) will include all patients with a confirmed HT-1 diagnosis on Nitisinone treatment in routine clinical care, who provide signed informed consent. Patients must be either on treatment with Nitisinone at study entry or they must have been prescribed Nitisinone at enrollment. No specific exclusion criteria from the analysis set will be applied. The FAS will be used for all analyses.